Tarsus Pharmaceuticals (TARS) Research & Development (2019 - 2026)

Tarsus Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $22.4 million for Q1 2026.

• On a quarterly basis, Research & Development rose 55.12% year-over-year to $22.4 million in Q1 2026; TTM through Mar 2026 was $72.3 million, a 29.67% increase from a year earlier, with the FY2025 full-year figure at $64.3 million, up 20.48% from the prior year.
• Research & Development grew to $22.4 million in Q1 2026 per TARS's latest filing, from $18.0 million in the prior quarter.
• Across five years, Research & Development topped out at $22.4 million in Q1 2026 and bottomed at $500000.0 in Q4 2022.
• The 5-year median for Research & Development is $12.4 million (2023), against an average of $13.1 million.
• Across the five-year window, Research & Development tumbled 93.78% in 2022 and surged 2561.0% in 2023, its largest moves.
• Year by year, Research & Development stood at $500000.0 in 2022, then jumped by 2561.0% to $13.3 million in 2023, then climbed by 26.82% to $16.9 million in 2024, then climbed by 6.89% to $18.0 million in 2025, then advanced by 23.93% to $22.4 million in 2026.
• Per Business Quant, the three latest TARS Research & Development figures stand at $22.4 million (Q1 2026), $18.0 million (Q4 2025), and $16.3 million (Q3 2025).